Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MRK 
Merck & Company Inc (MRK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/27/2025: MRK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $100.41
1 Year Target Price $100.41
| 12 | Strong Buy |
| 3 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.68% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 212.29B USD | Price to earnings Ratio 13.1 | 1Y Target Price 100.41 |
Price to earnings Ratio 13.1 | 1Y Target Price 100.41 | ||
Volume (30-day avg) 26 | Beta 0.39 | 52 Weeks Range 72.58 - 116.37 | Updated Date 08/27/2025 |
52 Weeks Range 72.58 - 116.37 | Updated Date 08/27/2025 | ||
Dividends yield (FY) 3.70% | Basic EPS (TTM) 6.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-29 | When Before Market | Estimate 2.06 | Actual 2.13 |
Profitability
Profit Margin 25.79% | Operating Margin (TTM) 37.47% |
Management Effectiveness
Return on Assets (TTM) 13.01% | Return on Equity (TTM) 35.42% |
Valuation
Trailing PE 13.1 | Forward PE 9.51 | Enterprise Value 239066595102 | Price to Sales(TTM) 3.34 |
Enterprise Value 239066595102 | Price to Sales(TTM) 3.34 | ||
Enterprise Value to Revenue 3.76 | Enterprise Value to EBITDA 9.55 | Shares Outstanding 2497779968 | Shares Floating 2493836714 |
Shares Outstanding 2497779968 | Shares Floating 2493836714 | ||
Percent Insiders 0.07 | Percent Institutions 80.54 |
Upturn AI SWOT
Merck & Company Inc
Company Overview
History and Background
Merck & Company Inc., founded in 1891 as the U.S. subsidiary of German Merck, is a global pharmaceutical company. Significant milestones include developing Vitamin B1, streptomycin (an early antibiotic), and successful cancer immunotherapy Keytruda. It has evolved from a chemical supplier to a leading research-driven healthcare company.
Core Business Areas
- Pharmaceuticals: Discovery, development, manufacturing, and marketing of a wide range of human health pharmaceutical products, including oncology, vaccines, hospital specialty, and cardiometabolic areas.
- Animal Health: Discovery, development, manufacturing, and marketing of animal health products, including vaccines, parasiticides, and other animal health products for livestock, poultry, and companion animals.
Leadership and Structure
Robert M. Davis is the current CEO. The company operates with a hierarchical structure, with various divisions reporting to executive leadership.
Top Products and Market Share
Key Offerings
- Keytruda: A leading cancer immunotherapy drug. Estimated global sales were ~$25 billion in 2023. Competitors include Bristol Myers Squibb's Opdivo and Roche's Tecentriq.
- Gardasil: A vaccine that prevents certain types of HPV. Sales were ~$9 billion in 2023. Competitors include GSK's Cervarix (though less prevalent).
- Januvia: A drug used to treat type 2 diabetes. Sales in 2023 were $3.3B, as the drug is now facing generics. Competitors include Novo Nordisk's Ozempic and Eli Lilly's Trulicity.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and patent protection. It is a growing market due to aging populations and increasing healthcare expenditure.
Positioning
Merck is a leading player in the pharmaceutical industry, with a strong focus on innovation and a diverse portfolio of products. Its competitive advantages include a robust pipeline of new drugs, a strong global presence, and established relationships with healthcare providers.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be worth over $1.4 trillion. Merck is well-positioned to capture a significant share of this market through its innovative products and strong market presence.
Upturn SWOT Analysis
Strengths
- Strong product portfolio
- Robust R&D pipeline
- Global presence and distribution network
- Successful oncology franchise (Keytruda)
- Strong animal health business
Weaknesses
- Reliance on key products (patent expiration risk)
- Exposure to generic competition
- High R&D expenditure
- Potential for product liability claims
- Dependence on regulatory approvals
Opportunities
- Expanding into emerging markets
- Developing new therapies for unmet medical needs
- Strategic acquisitions and partnerships
- Growth in the animal health market
- Leveraging digital health technologies
Threats
- Patent expirations and generic competition
- Increasing regulatory scrutiny
- Price pressures from governments and insurers
- Competition from other pharmaceutical companies
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- ABBV
- NVS
- MRNA
Competitive Landscape
Merck's advantages include Keytruda's dominance in oncology and a strong animal health business. Disadvantages include reliance on key products and exposure to generic competition.
Major Acquisitions
Imago BioSciences
- Year: 2022
- Acquisition Price (USD millions): 1.35
- Strategic Rationale: To expand Merck's hematology pipeline.
Growth Trajectory and Initiatives
Historical Growth: Merck has demonstrated consistent growth in revenue and earnings over the past several years, driven by its strong product portfolio and strategic acquisitions.
Future Projections: Analysts project continued growth for Merck, driven by Keytruda, Gardasil, and pipeline products. However, patent expirations and competition pose challenges.
Recent Initiatives: Recent initiatives include acquisitions to bolster the pipeline and investments in new manufacturing facilities. Divestitures of non-core business has simplified operations.
Summary
Merck is a strong pharmaceutical company with a leading oncology franchise and a robust pipeline. The company's financial performance is solid, and it has a history of rewarding shareholders. However, Merck faces challenges related to patent expirations and increasing competition which it needs to manage closely. The diversified portfolio and recent acquisition activity provide ample opportunity for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Merck & Company Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Merck & Company Inc
Exchange NYSE | Headquaters Rahway, NJ, United States | ||
IPO Launch date 1978-01-13 | Chairman, President & CEO Mr. Robert M. Davis J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 73000 | Website https://www.merck.com |
Full time employees 73000 | Website https://www.merck.com | ||
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and ant
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.